Literature DB >> 2525616

Dura versus Gore-Tex as an abdominal wall prosthesis in an open and closed infected model.

S Smith1, N Gantt, M I Rowe, D A Lloyd.   

Abstract

Occasionally, it is necessary to use prosthetic material to close large abdominal wall defects in infected, potentially infected, or open wounds. We compared the effectiveness of Gore-Tex (PTFE, W.L. Gore & Associates, Flagstaff, AZ) and dura for closing large, full thickness abdominal wall defects in terms of resistance to infection, patch separation, and intraperitoneal adhesion formation. Ninety guinea pigs had full thickness, 2 cm2, abdominal defects patched with either PTFE or dura. The skin was (A) left open (B) closed over the patch under aseptic conditions, or (C) closed after wound contamination with 10(5) CFU of staphylococcus aureus. Wounds were examined daily and the wound and peritoneal cavity examined at necropsy (day 45). Patch separation, patch retention, and adhesions were similar in both open (A), and clean closed (B) wounds patched with PTFE or dura. In the infected closed wounds (C) of the PTFE animals, the incision remained intact significantly longer, the time of patch separation and overall patch retention were significantly increased, and bowel adhesions were significantly reduced compared to dura animals.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2525616     DOI: 10.1016/s0022-3468(89)80496-8

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  10 in total

Review 1.  A critical review of the in vitro and in vivo models for the evaluation of anti-infective meshes.

Authors:  O Guillaume; B Pérez Kohler; R Fortelny; H Redl; F Moriarty; R G Richards; D Eglin; A Petter Puchner
Journal:  Hernia       Date:  2018-08-28       Impact factor: 4.739

2.  Autologous dermal grafts for rectus sheath reconstruction and application in closure of ventral myofascial defects.

Authors:  Warren M Rozen; Shivam Kapila; Morteza Enajat; Michelle J M L Tan; Iain S Whitaker; Rafael Acosta
Journal:  Updates Surg       Date:  2012-07-20

3.  The susceptibility of prosthetic biomaterials to infection.

Authors:  A M Carbonell; B D Matthews; D Dréau; M Foster; C E Austin; K W Kercher; R F Sing; B T Heniford
Journal:  Surg Endosc       Date:  2004-12-09       Impact factor: 4.584

4.  Reconstruction of the abdominal wall by using a combination of the human acellular dermal matrix implant and an interpositional omentum flap after extensive tumor resection in patients with abdominal wall neoplasm: a preliminary result.

Authors:  Yan Gu; Rui Tang; Ding-Quan Gong; Yun-Liang Qian
Journal:  World J Gastroenterol       Date:  2008-02-07       Impact factor: 5.742

5.  Abdominal wall reconstruction with mesh and components separation.

Authors:  Lior Heller; Chuma Chike-Obi; Amy Shengnan Xue
Journal:  Semin Plast Surg       Date:  2012-02       Impact factor: 2.314

6.  The use of a human dura mater allograft for the repair of a contaminated abdominal wall defect: report of a case.

Authors:  M Takahashi; K Ono; R Wakakuwa; O Sato; Y Tsuchiya; G Kamiya; K Nitta; K Tajima; K Wada
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

7.  [PAUL procedure. A new biocompatible concept for the therapy of congenital abdominal wall defects].

Authors:  T Meyer; A Seifert; B Meyer; K Ulrichs; C-T Germer
Journal:  Chirurg       Date:  2010-03       Impact factor: 0.955

8.  A new biocompatible material (Lyoplant) for the therapy of congenital abdominal wall defects: first experimental results in rats.

Authors:  Thomas Meyer; Karin Schwarz; Karin Ulrichs; Burkhard Höcht
Journal:  Pediatr Surg Int       Date:  2006-03-04       Impact factor: 1.827

Review 9.  The guinea pig as a model of infectious diseases.

Authors:  Danielle J Padilla-Carlin; David N McMurray; Anthony J Hickey
Journal:  Comp Med       Date:  2008-08       Impact factor: 0.982

10.  Emergent laparoscopic repair of incarcerated incisional and ventral hernia.

Authors:  O Landau; S Kyzer
Journal:  Surg Endosc       Date:  2004-05-28       Impact factor: 4.584

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.